HCV Market is Expected to Grow During the Forecast Period, According to a New Study on ASDReports

Friday 3 October 2014, Amsterdam

 The table above presents the key metrics for hepatitis virus C (HCV) in the nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China) during the forecast period from 2012–2022.

The HCV market generated approximately $4.2 billion from global sales in 2012. Over the next 10 years, this market is expected to grow to reach $12.8 billion, with major growth occurring in the main HCV markets, such the US.  Some of the main drivers of market growth are expected to be: 

•  Introduction of interferon-free HCV regimens, which have an improved side effect profile compared with the first-generation direct-acting antiviral (DAA) and interferon-sparing HCV therapies 
• The arrival of fixed-dose combination therapies, which are expected to help simplify treatment
• Increase in patient awareness of HCV through screening initiatives and public awareness campaigns
• A paradigm shift toward the preventative treatment of HCV in most countries

The barriers limiting the growth of the market include:

• Limited patient awareness regarding the threat of HCV
  

• Concerns over decreasing healthcare spending as part of government austerity measures